Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13966415 | 0.90 | CCNB2 (0.52) | SLC29A1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL17371116 | 0.90 | PI4KA (0.61) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21139430 | 0.90 | PI4KA (0.61) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13966414 | 0.90 | PI4KA (0.61) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13975624 | 0.90 | PI4KA (0.61) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17367923 | 0.88 | CCNB2 (0.50) | SLC29A1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL19443158 | 0.88 | CCNB2 (0.50) | SLC29A1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL20434991 | 0.86 | SLC29A1 (0.48) | SLC29A1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL20435006 | 0.86 | PI4KA (0.56) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20435009 | 0.86 | PI4KA (0.56) | SLC29A1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342818-B2 | Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases | ACADEMIA SINICA (TW) | 2019-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342818-B2 | Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases | ADORA2A, ADORA1, ADORA3 | SLC29A1 6/4885CCNB2 3474/4885CDK1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.